Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?

Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?

From: GRACEcast
0 0 7 years ago
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

Find us on Facebook